; or (B) may present a specific threat to the Armed Forces. (2) Factors In establishing and revising the list under paragraph (1), the Secretary may consider— (A) whether an eligible class or category of drugs that is identified is— (i) needed to protect the public health, using the same standard that applies with respect to determinations of material threats under section 319F–2(c)(2)(B)(ii) of the Public Health Service Act; and (ii) determined to be a priority (consistent with sections 302(2) and 304(a) of the Homeland Security Act of 2002); (B) for any class or category of drugs under consideration to address specific threats to the Armed Forces, information provided by the Secretary of Defense to help evaluate whether a priority review voucher is necessary and beneficial to incentivize product development for the Department of Defense use and fielding; (C) whether the class or category of drug requires incentivization in the form a priority review voucher based upon economic factors, such as whether there is a sufficient market to support the development of the potential medical countermeasures and the maturity of the medical countermeasure pipeline; (D) the potential effect of an addition of a class or category of drug on the potential sale value of priority review vouchers; and (E) such other factors as the Secretary determines appropriate. (3) Duties The Secretary, acting through the Assistant Secretary of Preparedness and Response, shall— (A) in coordination with the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Program, disclose to interested priority review applicants the list developed under paragraph (1); (B) periodically review the list developed under paragraph (1) for continued necessity and appropriateness, and add, amend, or remove any classes or categories of drugs if no longer necessary or appropriate